Literature DB >> 845257

Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.

J G Sissons, J Liebowitch, N Amos, D K Peters.   

Abstract

The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 845257      PMCID: PMC372275          DOI: 10.1172/JCI108689

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis.

Authors:  U R Nilsson; R H Tomar; F B Taylor
Journal:  Immunochemistry       Date:  1972-07

4.  Skin lesions, angio-oedema, and hypocomplementaemia.

Authors:  J G Sissons; D K Peters; D G Williams; J M Boulton-Jones; H J Goldsmith
Journal:  Lancet       Date:  1974-12-07       Impact factor: 79.321

5.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

6.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

7.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

8.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

9.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  18 in total

1.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.

Authors:  Y C Ng; D K Peters
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Complement activation in asymptomatic patients with sickle cell anaemia.

Authors:  W A Wilson; E J Thomas; J G Sissons
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

Review 4.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

5.  Use of the complement inhibitor Coversin to treat HSCT-associated TMA.

Authors:  Timothy H J Goodship; Fernando Pinto; Wynn H Weston-Davies; Juliana Silva; Jun-Ichi Nishimura; Miles A Nunn; Ian Mackie; Samuel J Machin; Liina Palm; Jeremy W Pryce; Robert Chiesa; Persis Amrolia; Paul Veys
Journal:  Blood Adv       Date:  2017-07-03

6.  Human fibronectin metabolism.

Authors:  B A Pussell; P W Peake; M A Brown; J A Charlesworth
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  Metabolism of human beta 1H: studies in man and experimental animals.

Authors:  J A Charlesworth; D M Scott; B A Pussell; D K Peters
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

8.  The complement system in type 1 (insulin-dependent) diabetes.

Authors:  J A Charlesworth; V Timmermans; J Golding; L V Campbell; P W Peake; B A Pussell; D Wakefield; N Howard
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

9.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

10.  Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.

Authors:  A J Swaak; A Hannema; C Vogelaar; F A Boom; L van Es; R van Aalst; L W Statius van Eps
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.